GlassScriptPhysician profile
Katrina Geannopoulos
NPI 1760132674
$717.87
in general payments reported to CMS, 2019-2025
16 companies · $718 in 2025
The $718 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $144.58 | 2025 | |
| Genentech USA, INC. | $103.18 | 2025 | Ocrevus Zunovo, Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $88.77 | 2025 | Hyqvia |
| Lundbeck LLC | $41.53 | 2025 | Vyepti |
| Ucb, INC. | $36.19 | 2025 | Briviact |
| Alnylam Pharmaceuticals INC. | $35.86 | 2025 | Onpattro |
| Teva Pharmaceuticals USA, INC. | $34.56 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $32.16 | 2025 | Wainua |
| Argenx US, INC. | $30.73 | 2025 | Vyvgart |
| Jazz Pharmaceuticals INC. | $27.90 | 2025 | |
| Amgen INC. | $27.60 | 2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $26.60 | 2025 | |
| Csl Behring | $24.72 | 2025 | Kcentra, Privigen |
| Tg Therapeutics, INC. | $24.50 | 2025 | |
| Emd Serono, INC. | $20.74 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $18.25 | 2025 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Geannopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.